Cambiotics ApS

Cambiotics ApS, located in Copenhagen, Denmark, focuses on developing precision-formulated probiotics aimed at eliminating per- and polyfluoroalkyl substances (PFAS) from the body, enhancing health and safety in affected populations. Cambiotics ApS, founded in 2024, specializes in probiotics that target PFAS elimination. The company raised EUR 4 million in Seed funding in February 2026 from Collaborative Fund, Export and Investment Fund of Denmark, and True. The founder's history is not specified, and there are no mentions of subsidiaries or pivots in operations.

Cambiotics specializes in the development of precision-formulated probiotics designed to support the body's natural processes for the removal of per- and polyfluoroalkyl substances (PFAS), commonly known as "forever chemicals. " Their core product is a unique probiotic formulation engineered to interact with PFAS molecules in the gut, facilitating their elimination through the digestive system. Targeting individuals exposed to PFAS through contaminated water, food, or consumer products, Cambiotics plans to release its probiotic product in the United States in 2026. The company also emphasizes its commitment to supporting first responders in managing PFAS exposure.

Cambiotics generates revenue primarily through the sale of its probiotic products, marketed directly to consumers and in partnership with healthcare providers and retail outlets. The business model involves direct-to-consumer sales, subscriptions for health management, and collaborations with healthcare institutions, addressing the broader issue of PFAS exposure while offering strategic partnerships for awareness and education around PFAS health risks. Cambiotics ApS plans to utilize the EUR 4 million raised in Seed funding to begin its first human clinical trial and prepare for the U. S.

launch of its PFAS-targeting probiotic supplement. The company aims to expand into markets across Europe, Asia, and Africa, with specific timelines yet to be established.